- Home
- MRT vs TLSI Comparison
MRT vs TLSI Comparison
Compare MRT & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- TLSI
- Stock Information
- Founded
- MRT 2018
- TLSI 2010
- Country
- MRT Turkey
- TLSI United States
- Employees
- MRT N/A
- TLSI N/A
- Industry
- MRT Rental/Leasing Companies
- TLSI Medical Specialities
- Sector
- MRT Consumer Discretionary
- TLSI Health Care
- Exchange
- MRT Nasdaq
- TLSI Nasdaq
- Market Cap
- MRT 228.0M
- TLSI 204.0M
- IPO Year
- MRT N/A
- TLSI N/A
- Fundamental
- Price
- MRT $2.99
- TLSI $4.89
- Analyst Decision
- MRT Strong Buy
- TLSI Strong Buy
- Analyst Count
- MRT 2
- TLSI 5
- Target Price
- MRT $6.00
- TLSI $10.90
- AVG Volume (30 Days)
- MRT 88.9K
- TLSI 153.7K
- Earning Date
- MRT 01-01-0001
- TLSI 08-13-2025
- Dividend Yield
- MRT N/A
- TLSI N/A
- EPS Growth
- MRT N/A
- TLSI N/A
- EPS
- MRT N/A
- TLSI N/A
- Revenue
- MRT $18,659,655.00
- TLSI $32,141,000.00
- Revenue This Year
- MRT $83.29
- TLSI $55.52
- Revenue Next Year
- MRT $106.66
- TLSI $54.76
- P/E Ratio
- MRT N/A
- TLSI N/A
- Revenue Growth
- MRT N/A
- TLSI 46.20
- 52 Week Low
- MRT $1.32
- TLSI $3.50
- 52 Week High
- MRT $3.89
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- MRT 51.40
- TLSI 42.89
- Support Level
- MRT $2.86
- TLSI $4.85
- Resistance Level
- MRT $3.04
- TLSI $5.11
- Average True Range (ATR)
- MRT 0.15
- TLSI 0.30
- MACD
- MRT 0.03
- TLSI -0.03
- Stochastic Oscillator
- MRT 63.33
- TLSI 13.45
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.